Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
Accenture
Colorcon
Fish and Richardson
Johnson and Johnson
UBS
Queensland Health
Cerilliant
Mallinckrodt

Generated: October 21, 2017

DrugPatentWatch Database Preview

Cangrelor - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for cangrelor and what is the scope of cangrelor patent protection?

Cangrelor
is the generic ingredient in one branded drug marketed by Chiesi Usa Inc and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cangrelor has one hundred and twenty-six patent family members in thirty-nine countries and one supplementary protection certificate in one country.

There is one drug master file entry for cangrelor. One supplier is listed for this compound.

Summary for Generic Name: cangrelor

US Patents:8
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: see list1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list15
Clinical Trials: see list17
Patent Applications: see list216
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:cangrelor at DailyMed

Pharmacology for Ingredient: cangrelor

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: cangrelor

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,716,261Maintenance of platelet inhibition during antiplatelet therapy► Subscribe
9,320,754Maintenance of platelet inhibition during antiplatelet therapy► Subscribe
8,871,736Maintenance of platelet inhibition during antiplatelet therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: cangrelor

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2011060066► Subscribe
Japan2016510738► Subscribe
New Zealand502073► Subscribe
Poland337970► Subscribe
CroatiaP20161443► Subscribe
Turkey200000006► Subscribe
Slovenia1000079► Subscribe
Australia5351598► Subscribe
Slovenia2276541► Subscribe
HungaryE031704► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CANGRELOR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0060France► SubscribePRODUCT NAME: CANGRELOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,NOTAMMENT UN SEL TETRASODIQUE; REGISTRATION NO/DATE: EU/1/15/994/001 20150323
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Colorcon
Teva
Queensland Health
Dow
Mallinckrodt
Citi
Federal Trade Commission
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot